港股異動 | 華虹半導體(1347.HK)直線拉昇大漲10% 擬發行人民幣股份於科創板上市
格隆匯3月21日丨華虹半導體(1347.HK)午後直線拉昇,一度大漲約10%至36.5港元。華虹半導體今日午間在港交所公吿,董事會批准可能發行人民幣股份及將該等人民幣股份在上交所科創板上市的初步建議。將予發行的人民幣股份(包括將因超額配股權(如有)獲行使而發行的人民幣股份)不得超過本公司經根據建議發行人民幣股份擬發行及配發的人民幣股份擴大後的已發行股本25%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.